Triggers, Risk Factors, and Medication Review
At a Glance
Calciphylaxis is most strongly associated with advanced kidney disease or dialysis, and risk may rise with warfarin, mineral-bone imbalance, obesity, diabetes, female sex, and low albumin. Medication changes should be made only with the care team.
While the exact cause of calciphylaxis isn’t always clear, researchers have identified several “triggers” and risk factors that make it more likely to occur. Understanding these can help you and your medical team make specific changes to your medications and daily routine that may slow the progression of the disease.
The Kidney Connection
The vast majority of people with calciphylaxis have advanced kidney disease or are on dialysis [1]. When your kidneys don’t work correctly, your body struggles to balance minerals like calcium and phosphate.
- Mineral-Bone Disorder: High levels of phosphate and a high calcium-phosphate product (a number your doctor calculates by multiplying your calcium and phosphate levels) are observationally linked as risk markers. Clinicians follow these trends, though there is no single target number to chase [1][2].
- Dialysis “Vintage”: The longer a person has been on dialysis, the higher their risk may be, possibly due to the long-term buildup of calcium in the small vessels [1][3].
- Parathyroid Hormone (PTH): This hormone controls calcium levels. While very high PTH is often seen, even “normal” levels can be present in calciphylaxis. However, managing severe hyperparathyroidism (overactive parathyroid glands) is a key part of treatment [1][4].
The Warfarin Warning
One of the most significant and well-documented triggers for calciphylaxis is the use of warfarin (Coumadin), a common blood thinner [1][5].
The Biological Mechanism (Matrix Gla Protein)
Your body has a built-in “shield” against calcification called Matrix Gla Protein (MGP). To work correctly, this protein needs Vitamin K. Warfarin works by blocking Vitamin K, which unintentionally “turns off” your MGP shield [6][7].
Individual Risk Factors
Beyond medications and kidney health, several personal factors can increase your risk:
- Obesity: A higher Body Mass Index (BMI) is a consistent risk factor, likely because fat tissue has a high concentration of the small vessels where calciphylaxis begins [1][3].
- Sex: Women are significantly more likely to develop calciphylaxis than men [1][10].
- Diabetes: Having diabetes alongside kidney disease further increases the risk of vessel damage [1][10].
- Low Albumin: Albumin is a protein in your blood. Low levels (which can signal malnutrition, illness, or chronic inflammation) are frequently seen in patients just before they develop calciphylaxis [1][11].
Standard Medication Changes
Upon diagnosis, your care team will likely perform a “medication sweep” to review potential triggers. Common changes include:
- Evaluating Warfarin: Because of the MGP link, doctors will evaluate the risks and benefits of safely switching patients from warfarin to a different type of blood thinner, such as heparin or certain newer oral anticoagulants. However, you must NEVER stop warfarin on your own. This switch must be carefully coordinated, especially if you have a mechanical heart valve, as some newer anticoagulants are not appropriate [12][11].
- Changing Phosphate Binders: Many dialysis patients take binders that contain calcium. In calciphylaxis, these may be replaced with non-calcium binders (like sevelamer or lanthanum) to avoid adding more calcium to the body [12][11].
- Reviewing Vitamin D and Calcium: Nutritional Vitamin D, active Vitamin D analogues, and calcium supplements may be paused depending on your specific lab results. Do not stop them without your team [12][13].
- Reviewing Steroids and Iron: In some cases, long-term use of corticosteroids (like prednisone) or certain types of iron supplements may be reviewed, though the evidence linking them to calciphylaxis is uncertain, so do not stop needed treatments based on this list [13][14].
By safely reviewing these triggers under medical supervision, you are helping your body “put the brakes” on the calcification process, which is the first step toward healing [12].
Common questions in this guide
What increases the risk of calciphylaxis?
Why is warfarin reviewed after a calciphylaxis diagnosis?
Should calcium-containing phosphate binders be changed?
Do vitamin D or calcium supplements need to be stopped?
How should my kidney team check my ongoing calciphylaxis risk?
Get notified when new evidence is published on Calciphylaxis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (14)
- 1
Calciphylaxis in chronic kidney disease: a systematic review of pathomechanisms and risk factors for calcific uremic arteriolopathy.
Søndergaard C, Nagarajah S, Shen J, et al.
Renal failure 2026; (48(1)):2710397 doi:10.1080/0886022X.2026.2710397.
PMID: 42572798 - 2
Risk factors for calciphylaxis in Chinese hemodialysis patients: a matched case-control study.
Liu Y, Zhang X, Xie X, et al.
Renal failure 2021; (43(1)):406-416 doi:10.1080/0886022X.2021.1884094.
PMID: 33641601 - 3
Calciphylaxis in peritoneal dialysis patients: a single center cohort study.
Zhang Y, Corapi KM, Luongo M, et al.
International journal of nephrology and renovascular disease 2016; (9()):235-241 doi:10.2147/IJNRD.S115701.
PMID: 27698566 - 4
The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial.
Floege J, Kubo Y, Floege A, et al.
Clinical journal of the American Society of Nephrology : CJASN 2015; (10(5)):800-7 doi:10.2215/CJN.10221014.
PMID: 25887067 - 5
Characterization of Risk Factors for Calciphylaxis in Hemodialysis Patients in the Fraser Health Renal Program - A Matched Case-Control Retrospective Review.
Jang A, Mark Ho MH, Yan L
Journal of pharmacy practice 2023; (36(6)):1424-1437 doi:10.1177/08971900221118444.
PMID: 36036088 - 6
Vascular Calcification in Chronic Kidney Disease: The Role of Vitamin K- Dependent Matrix Gla Protein.
Roumeliotis S, Dounousi E, Salmas M, et al.
Frontiers in medicine 2020; (7()):154 doi:10.3389/fmed.2020.00154.
PMID: 32391368 - 7
Warfarin and Vascular Calcification.
Poterucha TJ, Goldhaber SZ
The American journal of medicine 2016; (129(6)):635.e1-4.
PMID: 26714212 - 8
Vitamin K-Dependent Carboxylation of Matrix Gla Protein Influences the Risk of Calciphylaxis.
Nigwekar SU, Bloch DB, Nazarian RM, et al.
Journal of the American Society of Nephrology : JASN 2017; (28(6)):1717-1722 doi:10.1681/ASN.2016060651.
PMID: 28049648 - 9
The Role of Matrix Gla Protein (MGP) in Vascular Calcification.
Bjørklund G, Svanberg E, Dadar M, et al.
Current medicinal chemistry 2020; (27(10)):1647-1660 doi:10.2174/0929867325666180716104159.
PMID: 30009696 - 10
Risk Factors Associated With the Development of Calciphylaxis in Patients With Chronic Kidney Disease: A Systematic Review.
Ogah CO, Mohammed H, Gabra IM, et al.
Cureus 2024; (16(12)):e75314 doi:10.7759/cureus.75314.
PMID: 39776750 - 11
Calciphylaxis epidemiology, risk factors, treatment and survival among French chronic kidney disease patients: a case-control study.
Gaisne R, Péré M, Menoyo V, et al.
BMC nephrology 2020; (21(1)):63 doi:10.1186/s12882-020-01722-y.
PMID: 32101140 - 12
Ten tips on how to deal with calciphylaxis patients.
Chewcharat A, Nigwekar SU
Clinical kidney journal 2025; (18(4)):sfaf098 doi:10.1093/ckj/sfaf098.
PMID: 40600068 - 13
Calciphylaxis-as a drug induced adverse event.
Portales-Castillo I, Kroshinsky D, Malhotra CK, et al.
Expert opinion on drug safety 2019; (18(1)):29-35 doi:10.1080/14740338.2019.1559813.
PMID: 30574812 - 14
Perioperative Management of Calciphylaxis: Literature Review and Treatment Recommendations.
Strand N, Maloney J, Wu S, et al.
Orthopedic reviews 2022; (14(3)):37573 doi:10.52965/001c.37573.
PMID: 36034726
This page is for informational purposes and explains calciphylaxis risk factors and medication review; it does not constitute medical advice. Never stop warfarin, calcium, vitamin D, or another prescribed medicine without guidance from your nephrologist and other treating clinicians.